The normalized data was used to predict the
molecular formula based on additive ions,molecular ion peaks and fragment ions.And
then peaks were matched with the mzCloud(https://www.mzcloud.org/), mzVaultand
MassListdatabase to obtain the accuratequalitative and relative quantitative
results.Statistical analyses were performed using the statistical software R (R version
R-3.4.3),Python (Python 2.7.6 version) and CentOS(CentOS release 6.6),When data
were not normally distributed, normal transformations were attempted using of area
normalization method.
"],"repository":["MetaboLights"],"study_status":["Public"],"ptm_modification":[""],"instrument_platform":["Liquid Chromatography MS - negative - reverse-phase","Liquid Chromatography MS - positive - reverse-phase"],"chromatography_protocol":["UHPLC-MS/MS analyses were performed using a Vanquish UHPLC system
(ThermoFisher, Germany) coupled with an Orbitrap Q ExactiveTMHF-X mass
spectrometer (Thermo Fisher, Germany)in Novogene Co., Ltd. (Beijing, China).
Samples were injected onto a HypersilGoldcolumn (100×2.1 mm, 1.9μm) using a
12-min linear gradient at a flow rate of 0.2mL/min. The eluents for the positive and
negative polarity modes were eluent A (0.1% FA in Water) and eluent B
(Methanol).The solvent gradient was set as follows: 2% B, 1.5 min; 2-85% B, 3 min;
85-100% B, 10 min; 100-2% B, 10.1 min; 2% B, 12 min.
"],"publication":["LGG exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib."],"submitter_name":["丽婷 å¢"],"submitter_affiliation":["æµ·å大å¦"],"organism_part":["feces"],"technology_type":["mass spectrometry assay"],"disease":[""],"extraction_protocol":["Tissues (100 mg) were individually grounded with liquid nitrogen and the
homogenate wasresuspended with prechilled 80% methanol by well vortex. The
sampleswere incubated on ice for 5 min and then were centrifuged at 15,000 g, 4°C
for 20 min. Someof supernatant was diluted to final concentration containing 53%
methanol by LC-MS grade water.Thesamples were subsequently transferred to a fresh
Eppendorf tube and thenwere centrifuged at 15000 g, 4°C for 20 min. Finally, the
supernatant was injected into the LC-MS/MSsystem analysis
"],"organism":["Mus musculus"],"full_dataset_link":["https://www.ebi.ac.uk/metabolights/MTBLS13811"],"author":["Siyuan Shen. Hainan University. 1512181782@qq.com."],"data_transformation_protocol":["The raw data files generated by UHPLC-MS/MS were processed using the Compound
Discoverer 3.3 (CD3.3, ThermoFisher) to perform peak alignment, peak picking, and
quantitation for each metabolite. The main parameterswere set as follows: peak area
was corrected with the first sample; actual mass tolerance, 5ppm; signal intensity
tolerance, 30%; and minimum intensity, et al.After that, peak intensities were
normalized to the total spectral intensity.
"],"study_factor":["Treatment"],"submitter_email":["1512181782@qq.com"],"sample_collection_protocol":["Fecal samples were collected from mice after a 12-hour fast prior to sacrifice and stored at -80°C.
"],"omics_type":["Metabolomics"],"study_design":["gefitinib","Lung Non-Small Cell Carcinoma","Lactobacillus rhamnosus","untargeted metabolite profiling"],"curator_keywords":["gefitinib","Lung Non-Small Cell Carcinoma","Lactobacillus rhamnosus","untargeted metabolite profiling"],"mass_spectrometry_protocol":["Q ExactiveTM HF mass
spectrometer was operated in positive/negative polarity mode with spray voltage of
3.5 kV, capillary temperature of 320°C, sheath gas flow rate of 35 psi and aux gas
flow rate of 10 L/min, S-lens RF level of 60, Aux gas heater temperature of 350°C.
"],"additional_accession":[]},"is_claimable":false,"name":"Lactobacillus rhamnosus GG (LGG) exhibits inhibitory effects against non-small cell lung cancer (NSCLC) and alleviates the adverse effects associated with gefitinib_Fecal metabolomics study in mice","description":"After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and in vitro experiments.
","dates":{"publication":"2026-09-03","submission":"2026-01-31"},"accession":"MTBLS13811","cross_references":{}}